ClinicalTrials.gg
CompletedNCT06848075Updated Nov 16, 2026Results posted

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

A Phase 2 interventional study of Elismetrep (K-304) 2 mg and Elismetrep (K-304) 5 mg in Migraine, sponsored by TriGemX Bio, Inc.. Completed at 66 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by TriGemX Bio, Inc. · Phase 2, Interventional, and Treatment

Updated Nov 16, 2026Posted results revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
431
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 696 studies in Migraine Disorders with a site in United States — 93 open to participants now, 115 under way, 27 of them phase 3. Migraine Disorders · United States.

Enrollment
123rd of 609
431 · median 78
Started
2025
with 31 others
Phase 2
90 of 696
7 open now
Registered
639th of 696
by date

Among the 696 studies in Migraine Disorders with a site in United States, this one is the 123rd largest by enrollment of the 609 interventional ones that give a count, is one of 32 that started in 2025, is one of 90 in phase 2, and was the 639th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

93 of the 696 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 696 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.

03

Conditions studied

  • Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be a male or female, age 18 to 70 years, inclusive, at the time of signing .
  2. Participant has greater than a one-year history of migraine with or without aura as defined by International Conference on Harmonization (IHS) criteria 1.1 and 1.2 and his/her migraines typically last between 4 to 72 hours, if untreated as documented in the participant's medical records from his/her treating physician and confirmed by the investigator.
  3. Participant has had ≥2 and ≤10 moderate or severe migraine attacks per month in each of the two months prior to screening (Visit 1).
  4. Meet the following requirements:

    1. Is a male OR
    2. Is a female who is of non- defined by at least 1 of the following criteria:
    3. (aged >45 years and with a minimum of 12 months of spontaneous amenorrhea with a screening serum follicle-stimulating hormone (FSH) level in the menopausal range established for the central laboratory.
    4. Post hysterectomy, bilateral oophorectomy or bilateral salpingectomy, based on the participant's recall of their medical history.

      OR

    5. Is a female of and:
    6. agrees to remain abstinent from heterosexual activity*

      *Abstinence can be used as the sole method of if it is in line with the participant's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.

    7. or agrees to use (or have their partner use) a birth control method that is acceptable from the first dose of study drug until the end of trial (EoT) visit. Acceptable methods of birth control are:

      • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

        • oral
        • intravaginal
        • transdermal
      • progestogen-only hormonal contraception associated with inhibition of ovulation:

        • oral
        • injectable
        • implantable
      • intrauterine device (IUD)
      • intrauterine hormone-releasing system (IUS)
      • bilateral tubal occlusion
      • vasectomised partner
      • sexual abstinence
      • progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action
      • male or female condom with or without spermicide
      • cap, diaphragm or sponge with spermicide
      • A combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods)

    This condition is waived if the participant is proven to have no child-bearing potential (eg, hysterectomy).

  5. Participant voluntarily agrees to participate in the study by giving written informed consent.
  6. Participant is able to read, understand and complete the study questionnaires and diary.
  7. Be willing and able to comply with the study schedule of visits, all trial procedures and restrictions.
  8. Be willing to use their own personal, qualified smartphone to download study specific eDiary applications for use during the study.

Exclusion criteria

Exclusion Criteria:

  1. Is a female who is pregnant, breast-feeding or intends to become pregnant during the planned course of the study. Note: Participants must have a negative serum pregnancy test (β-human chorionic gonadotropin (β-hCG)) performed by the central laboratory prior to enrollment in the study and negative urine pregnancy result at the randomization visit.

    Migraine history related

  2. Participant has difficulty distinguishing his/her migraine attacks from tension-type headaches.
  3. Participant has a history of predominantly mild migraine attacks or migraines that usually resolve spontaneously in less than two hours.
  4. Participant has more than 15 headache-days per month or has taken medication for acute headache on more than 10 days per month in any of the three months prior to screening (Visit 1).
  5. Participant has brainstem (a.k.a. basilar-type) or hemiplegic migraine headache, or retinal migraine.
  6. Participant was >50 years old at age of first migraine onset.
  7. Participant is taking migraine prophylactic medication where the prescribed daily dose has changed during the 3 months prior to screening (Visit 1) or anticipates any change during the study. Any withdrawal of preventive medications for the treatment of migraine should be completed at least 30 days prior to screening.

    Medical history related

  8. Participant has, in the opinion of the investigator, other confounding pain syndromes, psychiatric conditions such as uncontrolled major depression, history of psychosis, dementia or significant neurological disorders other than migraine [participants who are currently being treated with non-prohibited medication for depression and symptoms are well controlled, in the opinion of the investigator, are eligible to participate in this study].
  9. Participant is at imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicidality Severity Rating Scale (C-SSRS), or of harm to others in the opinion of the investigator. Participants must be excluded if they report suicidal ideation with intent, with or without a plan (i.e., Type 4 or 5 on the C-SSRS) in the past 2 months or suicidal behavior in the past 6 months.
  10. Has a recent history (within the past 3 years of the Screening Visit) or current diagnosis or evidence of endocrine, hematological, immunological, renal, respiratory, neurologic, gastrointestinal, biliary, or genitourinary abnormalities or diseases that, per the investigator's judgement, may jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.
  11. Has a history of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed if they have received treatment and follow-up consistent with local standard of care.
  12. Participant history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Participants with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or (TIA) during the 6 months prior to screening.
  13. Has a history of disease.
  14. Participant has a history of gastric or small intestinal surgery (including gastric bypass surgery or banding but not including cholecystectomy or appendectomy) or has a disease that causes malabsorption.

    Laboratory, vital sign, and (ECG) related

  15. Has a positive test result at screening for surface antigen (Ag), virus antibody.
  16. Has a screening estimated (eGFR) estimated with the Modification of Diet in Renal Disease (MDRD) equation of \<45 ml/min/1.73 m\^2.
  17. Has a screening result for or aspartate aminotransferase (ALT or AST) of >2.0X (ULN) or total >1.5X ULN at the Screening Visit. Note: An isolated bilirubin >1.5X ULN is acceptable if bilirubin is fractionated, and direct bilirubin is within the laboratory normal range.
  18. Has a interval to Fridericia's formula (QTcF) >450 milliseconds (msec) for males and >470 msec for females at screening.
  19. Has a mean value for triplicate seated systolic blood pressure >160 mmHg and/or diastolic blood pressure (BP) >95 mmHg measured after at least 5 minutes at rest at the Screening Visit.

    Note: If a participant's BP is exclusionary on the first triplicate assessment at the Screening Visit, they may have 1 repeat triplicate BP assessment at that visit after another rest of at least 10 minutes.

    Medication use and substance abuse related

  20. Has known history of or suspected abuse of alcohol or recreational drugs at screening.
  21. Has use of soft drugs (such as marijuana or any substances containing tetrahydrocannabinol (THC) or cannabidiol (CBD)) within 3 months prior to screening, or hard drugs (such as cocaine, illicit narcotics/opiates) within 6 months prior to screening.
  22. Has a positive drug screen at screening. Note: If benzodiazepines are detected on the drug screen, this is not exclusionary if they are prescribed a benzodiazepine for a therapeutic purpose (e.g. for insomnia) and confirmatory documentation is obtained from the prescribing physician.
  23. Is currently in violation of study requirements for prohibited and permissible concomitant medications (not already specified in other criteria) or is anticipated to violate these requirements during study participation.
  24. Has any use of prescription opiate medications within 14 days of screening or any anticipated/potential use of opiates during study participation.
  25. History of use of ergotamine medications on greater than/equal 10 days per month on a regular basis for greater than/equal 3 months prior to screening.
  26. History of non-narcotic analgesic intake on greater than/equal 15 days per month for greater than/equal 3 months prior to screening.

    Other

  27. Has known or suspected to trial product(s) or related products.
  28. Has a history of multiple significant and/or any severe allergies (e.g., food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food.
  29. Has any surgery scheduled for the duration of the trial.
  30. Had major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the Screening Visit; has a screening \<11.0 g/dL (males) or \<10.0 g/dL (females), or has a known hemoglobinopathy (e.g. sickle cell anemia, hemolytic anemia).
  31. Has previous participation in this trial. Participation is defined as signed .
  32. Has participated in any clinical trial of an approved or non-approved biological medicinal product (e.g. antibody therapy) within 90 days of screening or has participated in any clinical trial of an approved or non-approved investigational small molecule medicinal product within 30 days or 5 half-lives (whichever is longer) of screening.
  33. Has any other disorder, unwillingness or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.
  34. Is an employee or immediate family member (e.g., spouse, parent, child, sibling) of the Sponsor or study site.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
431 participants (actual)

Study arms

  • Experimental
    Elismetrep (K-304) Dose Level 1

    Participants received a single dose of elismetrep 2 mg

    Drug: Elismetrep (K-304) 2 mg

  • Experimental
    Elismetrep (K-304) Dose Level 2

    Participants received a single dose of elismetrep 5 mg

    Drug: Elismetrep (K-304) 5 mg

  • Experimental
    Elismetrep (K-304) Dose Level 3

    Participants received a single dose of elismetrep 10 mg

    Drug: Elismetrep (K-304) 10 mg

  • Experimental
    Elismetrep (K-304) Dose Level 4

    Participants received a single dose of elismetrep 20 mg

    Drug: Elismetrep (K-304) 20 mg

  • Placebo comparator
    Placebo

    Participants received a single dose of elismetrep-matched placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Pain Freedom

    Assessed using the number of evaluable participants that reported no pain at 2 hours post-dose. Pain was measured on a 4-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe)

    Time frame: 2 hours post-dose

Secondary outcomes

  1. Freedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia or Photophobia)

    Assessed using the number of evaluable participants that reported the absence of their MBS

    Time frame: 2 hours post-dose

  2. Pain Relief

    Assessed using the number of evaluable participants that reported a pain level of moderate or severe (responses of 2 or 3 on the 4-point Likert scale) at baseline and then reported a pain level of none or mild (response of 0 or 1).

    Time frame: 2 hours post-dose

  3. Freedom From Photophobia

    Assessed by tabulating the number of participants that reported the absence of photophobia at 2 hours post-dose in the subset of participants that reported the presence of photophobia at baseline.

    Time frame: 2 hours post-dose

  4. Freedom From Phonophobia

    Assessed by tabulating the number of participants that reported the absence of phonophobia at 2 hours post-dose in the subset of participants that reported the presence of phonophobia at baseline.

    Time frame: 2 hours post-dose

  5. Freedom From Nausea

    Assessed by tabulating the number of participants that reported the absence of nausea at 2 hours post-dose in the subset of participants that reported the presence of nausea at baseline.

    Time frame: 2 hours post-dose

  6. The Probability of Requiring Rescue Medication

    Assessed using the number of participants that took rescue medication within 24 hours after administration of study therapy

    Time frame: 24 hours post-dose

  7. Sustained Pain Freedom

    Assessed using the number of participants that did not experience any headache pain through the time period of interest

    Time frame: From 2 to 24 hours

  8. Sustained Pain Relief

    Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest.

    Time frame: From 2 to 24 hours

  9. Sustained Pain Freedom

    Assessed using the number of participants that did not experience any headache pain through the time period of interest.

    Time frame: From 2 to 48 hours

  10. Sustained Pain Relief

    Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest.

    Time frame: From 2 to 48 hours

  11. Proportion of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs)

    Time frame: up to 7 days after administration of study therapy

  12. Proportion of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs)

    Serious adverse events were assessed in the Safety Analysis Set.

    Time frame: Up to 7 days after administration of study therapy

07

Results

Posted Aug 27, 2026

Participant flow

Participant flow — Overall Study
MilestoneElismetrep (K-304) 2 mgElismetrep (K-304) 5 mgElismetrep (K-304) 10 mgElismetrep (K-304) 20 mgPlacebo
Started5410710854108
Completed5410610654106
Not completed01202
Withdrew: Lost to follow-up01202

Outcome measures

PrimaryPain Freedom

Assessed using the number of evaluable participants that reported no pain at 2 hours post-dose. Pain was measured on a 4-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe)

Time frame:
2 hours post-dose
Reported as:
Count of participants · Participants
Pain Freedom
ParticipantsElismetrep (K-304) 2 mgElismetrep (K-304) 5 mgElismetrep (K-304) 10 mgElismetrep (K-304) 20 mgPlacebo
Pain Freedom4101099
Statistical analysis
  • Elismetrep (K-304) 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.4002 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses. The 90% confidence interval (CI) and p-value were derived.) · Risk difference (rd): -1.23 · 90% CI -9.04 to 6.57The 90% CI and p-value are derived from the Cochran-Mantel-Haenszel (CMH) test stratified by background prophylactic medications for migraine (yes/no)
  • Elismetrep (K-304) 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.4240 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 0.80 · 90% CI -6.02 to 7.62The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3774 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 1.33 · 90% CI -5.66 to 8.32The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0650 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 8.54 · 90% CI -1.45 to 18.52The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
SecondaryFreedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia or Photophobia)

Assessed using the number of evaluable participants that reported the absence of their MBS

Time frame:
2 hours post-dose
Reported as:
Count of participants · Participants
Freedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia or Photophobia)
ParticipantsElismetrep (K-304) 2 mgElismetrep (K-304) 5 mgElismetrep (K-304) 10 mgElismetrep (K-304) 20 mgPlacebo
Freedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia or Photophobia)1238281823
Statistical analysis
  • Elismetrep (K-304) 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3511 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 3.05 · 90% CI -10.24 to 16.34The 90% CI and p-value are derived from CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0122 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 15.25 · 90% CI 4.30 to 26.21The 90% CI and p-value are derived from CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1199 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 7.87 · 90% CI -3.10 to 18.84The 90% CI and p-value are derived from CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0425 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 14.04 · 90% CI 0.14 to 27.93The 90% CI and p-value are derived from CMH test stratified by background prophylactic medications for migraine (yes/no).
SecondaryPain Relief

Assessed using the number of evaluable participants that reported a pain level of moderate or severe (responses of 2 or 3 on the 4-point Likert scale) at baseline and then reported a pain level of none or mild (response of 0 or 1).

Time frame:
2 hours post-dose
Reported as:
Count of participants · Participants
Pain Relief
ParticipantsElismetrep (K-304) 2 mgElismetrep (K-304) 5 mgElismetrep (K-304) 10 mgElismetrep (K-304) 20 mgPlacebo
Pain Relief2956503042
Statistical analysis
  • Elismetrep (K-304) 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0479 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 14.43 · 90% CI 0.39 to 28.47The 90% CI and p-value are derived from CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0339 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 12.99 · 90% CI 1.44 to 24.53The 90% CI and p-value are derived from CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0891 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 9.66 · 90% CI -2.04 to 21.36The 90% CI and p-value are derived from CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0293 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 16.40 · 90% CI 2.42 to 30.38The 90% CI and p-value are derived from CMH test stratified by background prophylactic medications for migraine (yes/no).
SecondaryFreedom From Photophobia

Assessed by tabulating the number of participants that reported the absence of photophobia at 2 hours post-dose in the subset of participants that reported the presence of photophobia at baseline.

Time frame:
2 hours post-dose
Reported as:
Count of participants · Participants
Freedom From Photophobia
ParticipantsElismetrep (K-304) 2 mgElismetrep (K-304) 5 mgElismetrep (K-304) 10 mgElismetrep (K-304) 20 mgPlacebo
Freedom From Photophobia1123181326
Statistical analysis
  • Elismetrep (K-304) 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.4176 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): -1.81 · 90% CI -16.05 to 12.43The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.4490 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): -0.91 · 90% CI -12.51 to 10.69The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.2399 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): -4.95 · 90% CI -16.50 to 6.61The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3515 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 3.37 · 90% CI -11.37 to 18.12The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
SecondaryFreedom From Phonophobia

Assessed by tabulating the number of participants that reported the absence of phonophobia at 2 hours post-dose in the subset of participants that reported the presence of phonophobia at baseline.

Time frame:
2 hours post-dose
Reported as:
Count of participants · Participants
Freedom From Phonophobia
ParticipantsElismetrep (K-304) 2 mgElismetrep (K-304) 5 mgElismetrep (K-304) 10 mgElismetrep (K-304) 20 mgPlacebo
Freedom From Phonophobia1229231122
Statistical analysis
  • Elismetrep (K-304) 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.2743 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 6.08 · 90% CI -11.17 to 23.33The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0753 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 11.79 · 90% CI -1.52 to 25.11The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1757 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 7.87 · 90% CI -6.03 to 21.77The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.2191 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 8.19 · 90% CI -9.63 to 26.02The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
SecondaryFreedom From Nausea

Assessed by tabulating the number of participants that reported the absence of nausea at 2 hours post-dose in the subset of participants that reported the presence of nausea at baseline.

Time frame:
2 hours post-dose
Reported as:
Count of participants · Participants
Freedom From Nausea
ParticipantsElismetrep (K-304) 2 mgElismetrep (K-304) 5 mgElismetrep (K-304) 10 mgElismetrep (K-304) 20 mgPlacebo
Freedom From Nausea1225241323
Statistical analysis
  • Elismetrep (K-304) 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.4682 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 1.06 · 90% CI -20.56 to 22.68The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3643 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 3.75 · 90% CI -13.90 to 21.40The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1780 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 10.24 · 90% CI -7.82 to 28.31The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3696 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): -4.21 · 90% CI -24.68 to 16.26The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
SecondaryThe Probability of Requiring Rescue Medication

Assessed using the number of participants that took rescue medication within 24 hours after administration of study therapy

Time frame:
24 hours post-dose
Reported as:
Count of participants · Participants
The Probability of Requiring Rescue Medication
ParticipantsElismetrep (K-304) 2 mgElismetrep (K-304) 5 mgElismetrep (K-304) 10 mgElismetrep (K-304) 20 mgPlacebo
The Probability of Requiring Rescue Medication1524251627
Statistical analysis
  • Elismetrep (K-304) 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3937 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 2.10 · 90% CI -10.71 to 14.90The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.2748 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): -3.70 · 90% CI -13.82 to 6.41The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.4232 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): -1.23 · 90% CI -11.64 to 9.17The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3044 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 3.99 · 90% CI -8.92 to 16.89The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
SecondarySustained Pain Freedom

Assessed using the number of participants that did not experience any headache pain through the time period of interest

Time frame:
From 2 to 24 hours
Reported as:
Count of participants · Participants
Sustained Pain Freedom
ParticipantsElismetrep (K-304) 2 mgElismetrep (K-304) 5 mgElismetrep (K-304) 10 mgElismetrep (K-304) 20 mgPlacebo
Sustained Pain Freedom271067
Statistical analysis
  • Elismetrep (K-304) 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.2226 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): -3.15 · 90% CI -9.31 to 3.02The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.4849 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): -0.14 · 90% CI -6.07 to 5.79The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.2034 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 3.35 · 90% CI -3.29 to 9.98The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1689 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 4.68 · 90% CI -3.87 to 13.23The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
SecondarySustained Pain Relief

Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest.

Time frame:
From 2 to 24 hours
Reported as:
Count of participants · Participants
Sustained Pain Relief
ParticipantsElismetrep (K-304) 2 mgElismetrep (K-304) 5 mgElismetrep (K-304) 10 mgElismetrep (K-304) 20 mgPlacebo
Sustained Pain Relief1939341526
Statistical analysis
  • Elismetrep (K-304) 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0830 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 11.01 · 90% CI -2.30 to 24.32The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0306 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 12.47 · 90% CI 1.68 to 23.25The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0828 · Risk difference (rd): 9.16 · 90% CI -1.64 to 19.95
  • Elismetrep (K-304) 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3402 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 3.18 · 90% CI -9.58 to 15.95The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
SecondarySustained Pain Freedom

Assessed using the number of participants that did not experience any headache pain through the time period of interest.

Time frame:
From 2 to 48 hours
Reported as:
Count of participants · Participants
Sustained Pain Freedom
ParticipantsElismetrep (K-304) 2 mgElismetrep (K-304) 5 mgElismetrep (K-304) 10 mgElismetrep (K-304) 20 mgPlacebo
Sustained Pain Freedom26865
Statistical analysis
  • Elismetrep (K-304) 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3772 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): -1.15 · 90% CI -6.89 to 4.60The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.4004 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 0.82 · 90% CI -4.47 to 6.11The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1797 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 3.28 · 90% CI -2.61 to 9.18The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0697 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 6.68 · 90% CI -1.56 to 14.92The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
SecondarySustained Pain Relief

Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest.

Time frame:
From 2 to 48 hours
Reported as:
Count of participants · Participants
Sustained Pain Relief
ParticipantsElismetrep (K-304) 2 mgElismetrep (K-304) 5 mgElismetrep (K-304) 10 mgElismetrep (K-304) 20 mgPlacebo
Sustained Pain Relief1635291421
Statistical analysis
  • Elismetrep (K-304) 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0856 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 10.21 · 90% CI -2.45 to 22.87The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0164 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 13.61 · 90% CI 3.31 to 23.91The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0737 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 9.00 · 90% CI -1.14 to 19.14The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
  • Elismetrep (K-304) 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1929 (P-values are 1-sided. No multiplicity adjustments were made to account for multiple comparisons across primary and secondary endpoints and multiple doses.) · Risk difference (rd): 6.33 · 90% CI -5.91 to 18.57The 90% CI and p-value are derived from the CMH test stratified by background prophylactic medications for migraine (yes/no).
SecondaryProportion of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs)
Time frame:
up to 7 days after administration of study therapy
Reported as:
Count of participants · Participants
Proportion of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs)
ParticipantsElismetrep (K-304) 2 mgElismetrep (K-304) 5 mgElismetrep (K-304) 10 mgElismetrep (K-304) 20 mgPlacebo
Proportion of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs)3818214
SecondaryProportion of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs)

Serious adverse events were assessed in the Safety Analysis Set.

Time frame:
Up to 7 days after administration of study therapy
Reported as:
Count of participants · Participants
Proportion of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs)
ParticipantsElismetrep (K-304) 2 mgElismetrep (K-304) 5 mgElismetrep (K-304) 10 mgElismetrep (K-304) 20 mgPlacebo
Proportion of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs)00000

Adverse events

Collected over Up to 7 days after administration of study therapy. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Elismetrep (K-304) 2 mg0/51 (0%)0/51 (0%)2/51 (3.9%)
Elismetrep (K-304) 5 mg0/101 (0%)0/101 (0%)1/101 (1%)
Elismetrep (K-304) 10 mg0/97 (0%)0/97 (0%)10/97 (10.3%)
Elismetrep (K-304) 20 mg0/51 (0%)0/51 (0%)19/51 (37.3%)
Placebo0/104 (0%)0/104 (0%)0/104 (0%)
Most frequent other events
Most frequent other events
EventElismetrep (K-304) 2 mgElismetrep (K-304) 5 mgElismetrep (K-304) 10 mgElismetrep (K-304) 20 mgPlacebo
Feeling hotGeneral disorders0/510/1014/975/510/104
Paresthesia oralGastrointestinal disorders0/510/1012/975/510/104
Hot flushVascular disorders0/510/1011/974/510/104
ParesthesiaNervous system disorders0/510/1015/974/510/104
FlushingVascular disorders2/511/1014/973/510/104

Baseline characteristics

Modified Intent-to-Treat (ITT) Set including randomized participants who took study therapy, had a qualifying migraine of moderate or severe baseline pain intensity (Grade 2 or 3, on a 4-point numeric rating), and provided baseline and at least one post-baseline efficacy data point (i.e. non-missing pain level, phonophobia status, photophobia status, nausea status etc).

Age, Continuous
Age, Continuous(years)Elismetrep (K-304) 2 mgElismetrep (K-304) 5 mgElismetrep (K-304) 10 mgElismetrep (K-304) 20 mgPlaceboTotal
Mean44.5 ± 10.1344.5 ± 13.1246.1 ± 12.6847.4 ± 13.9646.5 ± 11.4445.8 ± 12.36
Sex: Female, Male
Sex: Female, Male(Participants)Elismetrep (K-304) 2 mgElismetrep (K-304) 5 mgElismetrep (K-304) 10 mgElismetrep (K-304) 20 mgPlaceboTotal
Female4389864484346
Male8121071552
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Elismetrep (K-304) 2 mgElismetrep (K-304) 5 mgElismetrep (K-304) 10 mgElismetrep (K-304) 20 mgPlaceboTotal
American Indian or Alaska Native001012
Asian2221411
Native Hawaiian or Other Pacific Islander000000
Black or African American9241071767
White4071814374309
More than one race022015
Unknown or Not Reported020024
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Elismetrep (K-304) 2 mgElismetrep (K-304) 5 mgElismetrep (K-304) 10 mgElismetrep (K-304) 20 mgPlaceboTotal
Hispanic or Latino5111161245
Not Hispanic or Latino4689844487350
Unknown or Not Reported011103
08

Study locations

66 sites
  • Central Research Associates, LLC (CRA) dba Flourish Research
    Birmingham, Alabama 35205, United States
  • AMR Mobile
    Mobile, Alabama 36608, United States
  • Wake Research/ Tucson Neuroscience Research
    Tucson, Arizona 85710, United States
  • Hope Clinical Research
    Canoga Park, California 91303, United States
  • WR-PRI, LLC (Encino)
    Encino, California 91316, United States
  • Marvel Clinical Research
    Huntington Beach, California 92647, United States
  • Eximia Research - CA
    La Mesa, California 91942, United States
  • Synergy San Diego
    Lemon Grove, California 91945, United States
  • WR-PRI, LLC (Newport Beach)
    Newport Beach, California 92660, United States
  • Excell Research, Inc.
    Oceanside, California 92056, United States
  • Empire Clinical Research
    Pomona, California 91767, United States
  • Artemis Institute for Clinical Research - Riverside
    Riverside, California 92503, United States
  • Acclaim Clinical Research
    San Diego, California 89109, United States
  • Artemis Institute for Clinical Research - San Diego
    San Diego, California 92103, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Focus Clinical Research
    West Hills, California 91307, United States
  • CT Clinical Research
    Cromwell, Connecticut 06416, United States
  • DelRicht Research
    Atlanta, Georgia 30329, United States
  • Clinical Research Atlanta - Stockbridge
    Stockbridge, Georgia 30281, United States
  • Northwest Clinical Trials
    Boise, Idaho 83704, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • Healthcare Research Network II, LLC
    Flossmoor, Illinois 60422, United States
  • Collective Medical Research
    Overland Park, Kansas 66202, United States
  • Alliance for Multispecialty Research
    Wichita, Kansas 67207, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Crescent City Headache & Neurology Center
    Chalmette, Louisiana 70043, United States
  • DelRicht Research
    New Orleans, Louisiana 70115, United States
  • Michigan Head Pain and Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Clinical Research Institute
    Minneapolis, Minnesota 55402, United States
  • DelRicht Research
    Gulfport, Mississippi 39503, United States
  • Healthcare Research Network
    Hazelwood, Missouri 63042, United States
  • Excel Clinical Research
    Las Vegas, Nevada 89109, United States
  • Las Vegas Clinical Trials
    North Las Vegas, Nevada 89119, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • Dent Neurosciences Research Center
    Amherst, New York 14226, United States
  • CNY Clinical Research
    Manlius, New York 13104, United States
  • Rochester Clinical Research
    Rochester, New York 14609, United States
  • Upstate Clinical Research Associates LLC
    Williamsville, New York 14221, United States
  • Headache Wellness Center
    Greensboro, North Carolina 27405, United States
  • Peters Medical Research
    High Point, North Carolina 27260, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • OK Clinical Research, LLC
    Edmond, Oklahoma 73034, United States
  • Hightower Clinical
    Oklahoma City, Oklahoma 73102, United States
  • DelRicht Research
    Tulsa, Oklahoma 74133, United States
  • Tekton Research
    Yukon, Oklahoma 73099, United States
  • Summit Research Network
    Portland, Oregon 97210, United States
  • Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18103, United States
  • Clinical Research Philadelphia, LLC
    Philadelphia, Pennsylvania 19114, United States
  • Frontier Clinical Research, LLC
    Scottdale, Pennsylvania 15683, United States
  • Frontier Clinical Research, LLC
    Smithfield, Pennsylvania 15478, United States
  • Atlas-Clinical
    West Chester, Pennsylvania 19380, United States
  • Clinical Trials of South Carolina
    Charleston, South Carolina 29406, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
  • WR-ClinSearch
    Chattanooga, Tennessee 37421, United States
  • AMR Knoxville (Formerly NOCCR)
    Knoxville, Tennessee 37909, United States
  • Clinical Research Associates, Inc.
    Nashville, Tennessee 37203, United States
  • Donald J Garcia Jr, MD, PA
    Austin, Texas 78737, United States
  • Tekton Research
    Austin, Texas 78745, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75251, United States
  • Victorium Clinical Research LTD CO
    Houston, Texas 77024, United States
  • APD Clinical Research
    Splendora, Texas 77372, United States
  • ClinPoint Trials
    Waxahachie, Texas 75165, United States
  • Advanced Research Institute
    Ogden, Utah 84405, United States
  • Health Research of Hampton Roads, Inc.
    Newport News, Virginia 23606, United States
  • Frontier Clinical Research, LLC
    Morgantown, West Virginia 26505, United States
  • Clinical Investigation Specialist
    Kenosha, Wisconsin 53144, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Aug 2025, 4 months.

Results were first posted in Aug 2026, 1 year after primary completion.

Of 43 industry-sponsored phase 2 interventional studies under Migraine Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 4 months is below that.

Counting every sponsor, half of 73 studies reached it within 15 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2025
First posted
Feb 26, 2025
StartActual
Mar 11, 2025
Primary completionActual
Aug 4, 2025
CompletionActual
Aug 4, 2025
Results first posted
Aug 27, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 20, 2026 · revised Nov 16, 2026
Show all 3 updates
  1. Nov 16, 2026
    Posted results revised
  2. Oct 20, 2026
    Posted results revised
  3. Sep 25, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06848075
Lead sponsor
TriGemX Bio, Inc.
Responsible party
Sponsor
First posted
Feb 26, 2025
Start date
Mar 11, 2025
Primary completion
Aug 4, 2025
Completion
Aug 4, 2025
Results posted
Aug 27, 2026
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elismetrep

Start the discussion